Royalty Report: Drugs, Cancer, Therapeutic – Collection: 415


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals
  • Disease
  • Drug Discovery
  • Antibody
  • Specialty
  • Technical Know How
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 544

License Grant
The parties desire that Licensor, an individual, transfer to Licensee all of Licensor's present and future right, title and interest in and to such intellectual property rights for the consideration and on the terms and conditions set forth in this Agreement, all as described more fully in this Agreement.
License Property
Licensor has independently designed and developed and owns certain intellectual property rights related to two-gene combination cancer vaccines, all as described more fully in this Agreement.

Technology –The term Technology shall mean (a) any United States or foreign patents that claim two-gene combination cancer vaccines and related technology that issue from, or claim priority to, United States patent application serial number 08/838,702 entitled Combination Immunogene Therapy or United States patent application serial number 09/826,025 entitled Combination Immunogene Therapy (or similar name) and related applications including continuations, continuations-in-part, divisional applications and requests for continuing examination (collectively, the Combination Immunogene Therapy Patent Applications).

Field of Use
The combination immunogene therapy technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

IPSCIO Record ID: 26298

License Grant
In August 2001, the Licensee acquired from Licensor, an individual, intellectual property rights and an assignment of a US patent application for combination immunogene therapy technology.
License Property
The technology was purchased from the Licensor, who developed it while at the University of Alberta, Edmonton, Canada.

IPSCIO Record ID: 367305

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patents and Licensed Technology to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Territory and in the Field of Use only.
License Property
Licensor owns one hundred percent interest in the Human Gene Therapy Research Institute located in Des Moines, Iowa.

Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.

The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
ATM Vector;
Dual adenoviral delivery of transgenes.

The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.

Field of Use
HyperAcute immunotherapies are designed to break tolerance and enable longer duration of anti-tumor effect.  HyperAcute immunotherapy technology has a wide range of anti-cancer applications including two additional product candidates, HyperAcute Lung and HyperAcute Melanoma, in active clinical development.  HyperAcute immunotherapy technology is designed to fight cancer by activating the human body's naturally protective and rapid immune response to the a-Gal carbohydrate.  HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which a-Gal is present by activating complement, an important component of the immune system that is capable of cell destruction. After destruction, we believe the resulting cellular fragments bound by anti-a-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

IPSCIO Record ID: 29247

License Grant
The Licensor granted an exclusive license to the patent, Tumor Radiosensitization Using Gene Therapy, for the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.
Field of Use
'Field' shall mean the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.

IPSCIO Record ID: 3044

License Grant
The Licensee acquired from Licensor, an individual, intellectual property rights and an assignment of a United States patent application for CIT technology, a proprietary cancer vaccine therapy technology, Combined Immunogene Therapy. The technology was purchased from the Licensee, who developed it while at the University of Alberta, Edmonton, Canada.

During 2003, two lawsuits were filed challenging the Licensor's ownership of this intellectual property. The value of the intellectual property will be diminished if either of the pending lawsuits regarding the same is successful. Governors of the University of Alberta filed against the Licensor and the Licensee in August 2003. The University of Alberta claims, among other things, that the Licensee failed to remit the payment of the University’s portion of the monies paid by the Licensor to the Licensee for the CIT technology purchased by the Licensor.

IPSCIO Record ID: 318779

License Grant
In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated and a royalty payment from the sale of IRX-2 was agreed upon to the Collaborator for a period of time.
License Property
IRX-2 is a novel cytokine-based therapy. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. IRX-2 is naturally derived from human blood cells.

IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.

Field of Use
The field of use is for the treatment of cancer relating to advanced head and neck squamous cell cancer.

The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.

IPSCIO Record ID: 344582

License Grant
The University grants a worldwide, exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, import, offer for Sale, and/or Sell licensed products for use within Field.
License Property
The University owns certain patent rights and Technology Rights related to Licensed Subject Matter.

The patents are titled

(a) U.S. Patent Application Number 60/092,672, filed July 13, 1998, entitled “Cancer Treatment Using Antibodies to Aminophospholipids” (UT SOUTHWESTERN File Reference UTSD0549PZ1);

(b) U.S. Patent Application Number 60/110,608, filed December 2, 1998, entitled “Cancer Treatment Using Antibodies to Aminophospholipids” (UT SOUTHWESTERN File Reference UTSD0549PZ2);

(c) U.S. Patent Application Number 09/351,543, filed July 12, 1999, entitled “ Cancer Treatment Methods Using Antibodies to Aminophospholipids” (UT SOUTHWESTERN File Reference UTSD0549);

(d) U.S. Patent Application Number 09/351,862, filed July 12, 1999, entitled “ Cancer Treatment Kits Using Antibodies to Aminophospholipids” (UT SOUTHWESTERN File Reference UTSD0549-1);

Field of Use
Bavituximab is our lead immunotherapy candidate  to evaluate the potential of bavituximab in combination with immune stimulating therapies.

Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (“PS”), a highly immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then “flips” and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. Bavituximab targets and binds to PS to block this immunosuppressive pathway and simultaneously activates adaptive immunity, thereby enabling the immune system to recognize and fight the tumor.

IPSCIO Record ID: 195780

License Grant
Licensor hereby grants to Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.  Patent Application is titled as “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”. Product Shall mean any materials including compositions, techniques, devices, methods or inventions relating to or based on the Licensed Patent Rights.
License Property
The invention teaches that cancer associated molecules, including production of glucocorticoids and HPA activation, have a general suppressive activity on the immune response which blocks ability to elicit effective anticancer immunity.

Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” and commercially named “MemoryMune”.

The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.

Field of Use
Licensee desires to use the rights to MemoryMune, a product derived from donor blood cells, developed to reawake dormant immune memory cells to develop marketable Product(s).

Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patient’s own immune system.  Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.

IPSCIO Record ID: 266679

License Grant
Licensor grants a worldwide exclusive license, with the right to assign or sublicense, to Licensors interest in any and all Joint Program IP and Program Information to allow Licensee to develop, market, promote, make, use, sell and import Compounds or Products or for any other purpose.

This research and collaboration agreement is to analyze and assess the potential clinical utility of certain compounds owned or licensed by Licensee.

License Property
Licensors IP means all Intellectual Property owned or Controlled by Licensor relating to Licensors  Biomerk Tumorgraftâ„¢ preclinical models.

Product means a preparation containing a Verified Compound having at least one indication for which Success has been predicted by Licensor under the Program.

Field of Use
The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology in conjunction with related services to offer solutions for two customer groups

Our Personalized Oncology Solutions (“POS) business which provides services to physicians and patients looking for information to help guide the development of a personalized treatment plans.

Our Translational Oncology Solutions (“TOS) business, which provides services to pharmaceutical and biotech companies seeking personalized approaches to drug development that will lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs.

Our technology platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. Our process technology involves the

implantation of human tumor fragments in immune compromised mice;

expansion of the original human tumor into a larger colony of mice through the passage of the tumor to subsequent generations of mice;

treatment of the implanted mice with oncology drugs;

measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine the response of the tumor to the drug.

Our process is used for our POS business to test numerous drugs or drug combinations against a single patient’s tumor to determine which therapy results in the most efficacious response from the tumor.

IPSCIO Record ID: 312594

License Grant
Licensors filed a complaint against Licensee in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 concerning CAR T cell technologies.

In April 2020, the Court granted in part Licensor’s motion and entered a final judgment awarding royalties on Licensee’s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.

License Property
CAR T refers to cell therapy.

Yescarta is a trademark of Licensee.   Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patient’s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.

Field of Use
Yescarta is cell therapy used in the treatment of cancer.  Licensee is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

IPSCIO Record ID: 29158

License Grant
The Licensee entered into a 20-year, last to expire Licensor patent rights exclusive worldwide License, with the Licensor with respect to the innovative work of a Professor of Microbiology in the area of innate immunity, or the immune response attributable to immune cells, including dentritic cells, macrophages and natural killer cells, that respond to pathogens non-specifically.
Field of Use
The Licensee uses the Listeria System Licensed from the Licensor to secrete a protein sequence containing a tumor-specific antigen. Using the Listeria System, the Licensee believes it will force the body’s immune system to process and recognize the antigen as if it were foreign, creating the immune response needed to attack the cancer.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.